Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 21-79~* Body mass index (BMI) of 30-40 kg/m2~* Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of \> 6.4% and/or fasting plasma glucose of \>125 mg/dL or current anti-diabetic medication)~* AA-induced platelet aggregation response of \>60% within 3 hours prior to initial dose of study drug administration~Exclusion Criteria:~* Contraindications to aspirin~* Previous history of vascular disease~* Patient requires insulin~* Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PL2200 Aspirin Capsules (Type: EXPERIMENTAL): Investigational drug arm; crossover design
- Immediate-Release Aspirin Tablets (Type: ACTIVE_COMPARATOR): Active comparator; crossover design
- Enteric-coated aspirin caplets (Type: ACTIVE_COMPARATOR): Active comparator; crossover design

Based on this trial design, predict the completion outcome and termination type (if applicable).